Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AROG4-01 in Advanced Solid Tumors
NCT06652529Phase 1Not yet recruiting
- Sponsor
- Aromics
- Start
- Jan 2025
- Primary completion
- Dec 2025
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of NAX035 in solid tumor (advanced stage) and mesothelioma (2 arms), sponsored by Aromics. Primary endpoint: Safety and tolerability of AROG4-01 at 12 months. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
NAX035
03
Conditions
solid tumor (advanced stage)mesothelioma
Beyond the preview
Go deeper on NCT06652529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06652529.